Want to join the conversation?
Pharma company $ALXN said its 3Q15 GAAP net loss was $0.81 per share, compared to diluted GAAP EPS of $0.88 in the third quarter of 2014. This was impacted by $315.6MM or $1.39 per share related to a non-cash deferred income tax expense resulting from the integration of Synageva.
$TSLA opening a showroom in Michigan. A bold move !!
$SGY is expected to achieve $6.17 price target in next year, with a minimum target of $3.00, due to the price increase of 27.85% to $6.29 during the last trading session.